Pathophysiological and clinical problems of cellular immunotherapy of digestive system cancer. Critical review
https://doi.org/10.20538/1682-0363-2009-3-105-112
Abstract
The review is devoted to the methods of bioimmunotherapy of oncological pathology used in the clinic for the recent 20—25 years and, to the higher extent, the principles of cellular immunotherapy of cancerous epithelial tumors of the digestive system. The surgical method is recognized as a «gold standard» in the therapy of the digestive system cancer. Bioimmunotherapy of the digestive system cancer has not achieved the sufficient clinical efficiency. In this connection, new pathophysiological approaches to biotherapy of the digestive system cancer based, in particular, on original results of Russian scientists are analyzed.
About the Authors
M. Yu. Khlusova
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
I. A. Khlusov
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
S. A. Antipov
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
G. Ts. Dambayev
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
References
1. Авцын А.П., Жаворонков А.А., Сирочкова А.С. Микроэлементозы человека: этиология, классификация, органопатология. М.: Медицина, 1991. 495 с.
2. Барышников А.Ю. Программированная клеточная смерть (апоптоз)//Клинич. онкогематология: Руководство для врачей/Под ред. М.А. Волковой. М.: Медицина, 2001. С. 36-42.
3. Биологические методы лечения онкологических заболеваний: пер. с англ./Под ред. В.Т. де Вита, С. Хеллмана, С.А. Розенберга. М.: Медицина, 2002. 936 с.
4. Владимирская Е.Б. Механизмы апоптотической смерти клеток//Гематология и трансфузиология. 2002. № 2. С. 5-40.
5. Гарин А.М., Базин И.С. Злокачественные опухоли пищеварительной системы. М.: Инфомедиа Паблишерз, 2003. 264 с.
6. Дамбаев Г.Ц., Гюнтер В.Э., Хлусов И.А. и др. Новые технологии в лечении онкопатологии//Бюл. СО РАМН. 2004. № 2. С. 67-73.
7. Моисеенко В.М. Биотерапия солидных опухолей//Вопр. онкологии. 1998. Т. 44. № 1. С. 120-127.
8. Моисеенко В.М., Балдуева И.А., Хансон К.И. Вакцинотерапия злокачественных опухолей//Вопр. онкологии. 1999. Т. 45, № 3. С. 327-332.
9. Пат. 2179578 РФ. Регулятор роста клеток in vitro и способ регуляции роста клеток in vitro/Дамбаев Г.Ц., Агафонников В.Ф., Хлусов И.А. и др.; от 20 февраля 2002 г.
10. СПОСОБ ЛЕЧЕНИЯ ОНКОЗАБОЛЕВАНИЙ Дамбаев Г.Ц., Гюнтер В.Э., Загребин Л.В., Хлусов И.А. патент на изобретение RUS 2285548 25.10.2004
11. Пат. 2290219 РФ. Способ обработки клеток in vitro/Хлусов И.А.; от 27.12.2006 г.
12. Розенберг С.А. Адоптивная иммунотерапия: клиническое применение//Биологические методы лечения онкологических заболеваний: пер. с англ./Под ред. В.Т. де Вита, С. Хеллмана, С.А. Розенберга. М.: Медицина, 2002. С. 504-522.
13. Топейлиен С.Л. Адоптивная клеточная терапия: преклинические исследования//Биологические методы лечения онкологических заболеваний: пер. с англ./Под ред. В.Т. де Вита, С. Хеллмана, С.А. Розенберга. М.: Медицина, 2002. С. 484-503.
14. Файерс У. Биологические методы лечения фактором некроза опухолей: преклинические исследования//Биологические методы лечения онкологических заболеваний: пер. с англ./Под ред. В.Т. де Вита, С. Хеллмана, С.А. Розенберга. М.: Медицина, 2002. С. 309-343.
15. Хлусов И.А. Возможности физико-химической регуляции пула стволовых клеток//Бюл. сиб. медицины. 2007. Т. 6, № 1. С. 7-12.
16. Хлусов И.А., Некрасова А.М., Севостьянова Н.В. и др. Лабораторные показатели как патогенетические маркеры прогрессирования рака пищеварительного тракта//Якут. мед. журн. 2007. Т. 20, № 4. С. 46-51.
17. Хлусов И.А., Некрасова А.М., Слепченко Г.Б. и др. Баланс микроэлементов и показатели гомеостаза как прогностические критерии при прогрессировании рака пищеварительного тракта//Сиб. онкол. журн. 2007. № 4. С. 72-81.
18. Энциклопедия клинической онкологии/Под ред. М.И. Давыдова. М.: РЛС-2005, 2004. 1456 с.
19. Aloysius M.M., Takhar A., Robins A. et al. Dendritic cell biology, dysfunction and immunotherapy in gastrointestinal cancers//Surgeon. 2006. V. 4, № 4. P. 195-210.
20. Berghella A.M., Contasta I., Pellegrini P. et al. Are immunological mechanisms involved in colon cancer and are they possible markers for biotherapy improvement?//Cancer Biother. Radiopharm. 2006. V. 21. № 5. P. 468-487.
21. Cai Y.G., Fang D.C., Chen L. et al. Dendritic cells reconstituted with a human heparanase gene induce potent cytotoxic T-cell responses against gastric tumor cells in vitro//Tumour Biol. 2007. V. 28, № 4. P. 238-246.
22. Correale P., Cusi M.G., Micheli L. et al. Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience//Invest. New Drugs. 2006. V. 24, № 2. P. 99-110.
23. Das P., Ajani J.A. Gastric and gastroesophageal cancer therapy//Expert Opin. Pharmacother. 2005. V. 6. № 16. P. 2805-2812.
24. Den Brok M.H., Nierkens S., Figdor C.G. et al. Dendritic cells: tools and targets for antitumor vaccination//Expert Rev. Vaccines. 2005. V. 4, № 5. P. 699-710.
25. Des Guetz G. Biotherapy in colorectal cancer//J. Chir (Paris). 2005. V. 142. № 5. P. 291-296.
26. Fraker P.J., King L.E. Reprogramming of the immune system during zinc deficiency//Annu. Rev. Nutr. 2004. V. 24. P. 277-298.
27. Hanna M.G. Jr, Hoover H.C. Jr, Pinedo H.M. et al. Active specific immunotherapy with autologous tumor cell vaccines for stage II colon cancer: logistics, efficacy, safety and immunological pharmacodynamics//Hum. Vaccin. 2006. V. 2, № 4. P. 185-191.
28. Hauteville D. Request for a compassionate use of biotherapies in oncology//Bull. Cancer. 2006. V. 93, № 11. P. 1152-1154.
29. Jiang J., Xu N., Wu C. et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytoline-induced killer cells//Anticancer Res. 2006. V. 26, № 3B. P. 2237-2242.
30. Kanazawa M., Yoshihara K., Abel H. et al. Two case reports on intra-tumor injection therapy of dendritic cells//Gan. To Kagaki Ryoho. 2005. V. 32, № 11. P. 1571-1573.
31. Kavanagh B., Ko A., Venook A. et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides//J. Imunother. 2007. V. 30, № 7. P. 762-772.
32. Khlusov I.A., Zagrebin L.V., Shestov S.S. et al. Physical-Chemical Manipulations with Microbial and Mammalian Cells: from Experiments to Clinics//Stem Cell Applications in Disease and Health/Ed. W.B. Burnsides et al. Nova Science Publishers, 2008. P. 29-71.
33. Koido S., Hara E., Homma S. et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells//Clin. Cancer Res. 2005. V. 11, № 21. P. 7891-7900.
34. Marits P., Karlsson M., Dahl K. et al. Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for use in immunotherapy of colon cancer//Br. J. Cancer. 2006. V. 94. № 10. P. 1478-1484.
35. Marshall J.L. Novel vaccines for the treatment of gastrointestinal cancers//Oncology. 2005. V. 19. P. 1557-1565.
36. Mocellin S., Campana L.G. Trends in colorectal cancer vaccination//Recenti Prog. Med. 2005. V. 96. № 7-8. P. 338-343.
37. Mocellin S. New strategies to improve the efficacy of colorectal cancer vaccines: from bench to bedside//Curr. Opin. Investig. Drugs. 2006. V. 7. № 12. P. 1052-1061.
38. Morse M.A. Virus-based therapies for colon cancer//Expert. Opin. Biol. Ther. 2005. V. 5, № 12. P. 1627-1633.
39. Nagorsen D., Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer//Clin. Cancer Res. 2006. V. 12, № 10. P. 3064-3069.
40. Oosterling S.J., van der Bij G.J., Mels A.K. et al. Perioperative IFN-alpha to avoid surgically induced immune suppression in colorectal cancer patients//Histol. Histopathol. 2006. V. 21, № 7. P. 753-760.
41. Osada T., Clay T., Hobeika A. et al. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity//Cancer Immunol. Immunother. 2006. V. 55, № 9. P. 1122-1131.
42. Park M.Y., Kim C.H., Sohn H.J. et al. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity//Vaccine. 2007. V. 25, № 42. P. 7322-7330.
43. Proudfoot O., Pouniots D., Sheng K.C. et al. Dendritic cell vaccination//Expert Rev. Vaccines. 2007. V. 6, № 4. P. 617-633.
44. Ravi R., Fuchs E.J., Jain A. et al. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling//Cancer Res. 2006. V. 66, № 3. P. 1730-1739.
45. Romano F., Cesana G., Caprotti R. et al. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients//Hepatogastroenterology. 2006. V. 53, № 70. P. 634-638.
46. Russell J.H., Rush B., Weaver C. et al. Mature T-cells of autoimmune Ipr/Ipr mice have a defect in antigen-stimulated suicide//Proc. Natl. Acad. Sci. USA. 1993. V. 90. P. 4409-4413.
47. Schimanski C.C., Horner V., Kanzler S. et al. Immunotherapy of colorectal cancer-overview and perspectives//Z. Gastroenterol. 2006. V. 44, № 8. P. 673-681.
48. Sutter A.P., Fechner H. Gene therapy for gastric cancer: is it promising?//World J. Gastroenterol. 2006. V. 12, № 3. P. 380-387.
49. Takeda T., Makita K., Okita K. et al. Intratumoral injection of immature dendritic cells (DC) for cancer patients//Gan. To Kagaki Ryoho. 2005. V. 32, № 11. P. 1574-1575.
50. Topalian S.L., Muul L.M., Solomon D. et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials//J. Immunol. Methods. 1987. V. 102. P. 127.
51. Vogiatzi P., Cassone M., Claudio P.P. Personalizing gene therapy in gastric cancer//Drug News Perspect. 2006. V. 19, № 9. P. 533-540.
52. Vose B.M., White W. Tumour-reactive lymphocytes stimulated in mixed lymphocyte and tumour culture//Cancer Immunol. Immunother. 1983. V. 15. P. 227.
53. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G. et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediated apoptosis//Nature. 1992. V. 356. P. 314-317.
54. Wu Y., Wang L., Zhang Y. Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy//Cell. Mol. Immunol. 2004. V. 1, № 5. P. 351-356.
55. Yamaguchi Y., Hihara J., Hironaka K. et al. Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: possible application for compensatory anti-inflammatory response syndrome//Oncol. Rep. 2006. V. 15, № 4. P. 895-901.
56. Yron I., Wood T.A., Spiess P.J. et al. In vitro growth of murine T cells. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors//J. Immunol. 1980. V. 125. P. 238.
Review
For citations:
Khlusova M.Yu., Khlusov I.A., Antipov S.A., Dambayev G.Ts. Pathophysiological and clinical problems of cellular immunotherapy of digestive system cancer. Critical review. Bulletin of Siberian Medicine. 2009;8(3):105-112. (In Russ.) https://doi.org/10.20538/1682-0363-2009-3-105-112
Views:
403
Email this article 